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In 2016, Guinea, Liberia, and Sierra Leone succeeded in interrupting the longest epidemic of 
Ebola virus disease in global history.1 Control of the epidemic was primarily achieved by 
implementation of effective and coordinated public health measures that involved rapid 
identification, isolation of cases, contact tracing, and isolation of contacts. However, the risk 
of re-emergence of Ebola virus disease is real, as shown by the 2017 and 2018 outbreaks in 
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the Democratic Republic of the Congo. Consequently, along with other public health 
measures, efforts to develop an effective vaccine against Ebola virus disease must continue.
As of June 18, 2018, 36 completed trials, seven active and not recruiting, and seven 
recruiting Ebola vaccine studies are registered on ClinicalTrials.gov. The only study that has 
been able to provide data on clinical efficacy is the Ebola Ça Suffit vaccination trial in 
Guinea.2 This open-label, cluster-randomised trial evaluated vaccine effectiveness in case 
contacts, where clusters of contacts of Ebola cases were randomised for immediate or 
delayed vaccination with the recombinant, replication-competent, vesicular stomatitis virus-
based vaccine expressing the glycoprotein of a Zaire Ebolavirus (rVSV-ZEBOV). Although 
the authors estimated the vaccine efficacy to be 100% (95% CI 68·9–100, p=0·0045)2 in 
individuals vaccinated in the immediate group compared with those eligible and randomised 
to the delayed group, the extent of this efficacy has been debated.3,4 A report by the US 
National Academies of Sciences, Engineering, and Medicine stated that “the results suggest 
that the vaccine most likely provides some protection to recipients—possibly ‘substantial 
protection,’ as stated in the final report. However, we remain uncertain about the magnitude 
of its efficacy”.4
Among other studies of this vaccine, the Partnership for Research on Ebola Vaccines in 
Liberia I (PREVAIL I) randomised, double-blind, placebo-controlled trial assessed the safety 
and immunogenicity of the rVSVZEBOV vaccine and the chimpanzee adenovirus type 3-
vectored Ebola virus vaccine (chAd3-EBO-Z) in 1500 adults.5 Compared with the placebo 
group, more participants in each vaccine group reported injection-site reactions and 
symptoms such as head ache, muscle pain, feverishness, and fatigue during the week 
following vaccination. These adverse effects were generally mild and time-limited. Over the 
12-month follow-up period, a similar number of serious adverse events were recorded 
among those vaccinated with the rVSV-ZEBOV vaccine (47 participants; 9%), the chAd3-
EBO-Z vaccine (40; 8%), and placebo (59; 12%). Most (71%) of the serious adverse events 
were attributed to malaria. Immunogenicity data at 1 month post vaccination, the time when 
the maximum antibody response was achieved, indicated that 71% of those given the chAd3-
EBO-Z vaccine and 84% of the rVSV-ZEBOV recipients, compared with 3% of those 
randomised to the placebo group, had an anti-Ebola glycoprotein antibody response. At 12 
months, antibody responses were 64% among those vaccinated with chAd3-EBO-Z and 80% 
among rVSV-ZEBOV recipients.
Additional safety and immunogenicity data on rVSVZEBOV have been generated in the 
Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE) study, which enrolled 
more than 8000 health-care and front-line workers in Sierra Leone,6 and in a trial in Guinea 
(the Front Line Worker trial [PACTR201503001057193] sponsored by WHO and Médecins 
Sans Frontières). There have also been eight phase 1 trials7–10 and a phase 3 safety and 
manufacturing-consistency trial11 of the rVSV-ZEBOV vaccine conducted in North 
America, Europe, and Africa. Collectively, trial data indicate that the rVSV-ZEBOV vaccine 
has an acceptable safety profile, and that it induces immunity that is durable for at least 24 
months in adults (antibody responses for 89–100% of recipients depending on the doses 
administered).12 Vaccination strategies involving rVSV-ZEBOV, although not yet licensed, 
are now used during epidemics through emergency authorisation. During May and June of 
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2018, more than 3000 individuals were vaccinated in the Democratic Republic of the Congo 
as part of the WHO response to the Ebola virus disease outbreak, according to the country’s 
Ministry of Health.13
Another promising vaccine candidate in advanced stages of development is an adenovirus 
type 26-vectored vaccine encoding Ebola virus glycoprotein (Ad26.ZEBOV), boosted by a 
modified vaccinia Ankara-vectored vaccine encoding glycoproteins from Ebola, Sudan, and 
Marburg viruses as well as the nucleoprotein of Tai Forest virus (MVA-BN-Filo). In a phase 
1 study of healthy volunteers (n=87),14 immunisation with Ad26.ZEBOV and MVA-BN-
Filo did not result in any vaccine-related serious adverse events. Seroconversion frequencies 
of 79–89% were observed as early as 14 days after prime vaccination with Ad26.ZEBOV. 
Boosting with MVA-BNFilo resulted in sustained elevation of specific immunity.14 
Published phase 1 data show that the combination of Ad26.ZEBOV and MVA-BN-Filo 
confers durable immunity for at least 360 days and is well tolerated with a good safety 
profile.15
The single-dose chAd3-EBO-Z vaccine regimen has also been studied in clinical trials,16,17 
with less-promising results, particularly regarding antibody responses.5 One trial tested a 
prime-boost strategy with chAd3 vaccine followed 2–3 months later by an MVA-BN-Filo 
booster.18 This strategy proved to be safe. Regarding its immunogenicity, the chAd3-EBO-Z 
vaccine boosted with MVA elicited B-cell and T-cell immune responses to ZEBOV that were 
superior to those induced by the chAd3-EBO-Z vaccine alone, and antibody responses 
remained positive 6 months after vaccination.19
Finally, the recombinant adenovirus type 5-vectored Ebola vaccine was safe and 
immunogenic in different trials.20–22 The GamEvac-Combi vaccine (live-attenuated 
recombinant vesicular stomatitis virus and recombinant adenovirus type 5 expressing the 
envelope glycoprotein of Ebola virus/H sapiens-wt/GIN/2014/Makona-C15 strain) was safe 
and induced strong humoral and cellular immune responses in up to 100% of 84 healthy 
adult volunteers.23
There are a number of unknowns regarding vaccination against Ebola virus. For example, 
few data have been generated in children. During the Ebola virus disease epidemic in west 
Africa, about 21% of patients with the disease were children aged 16 years or under, and the 
case fatality rate was more than 80% for children under 5 years of age.24 The index case of 
the epidemic was probably in a child aged 2 years.25 Thus, it is essential that these vaccines 
are assessed in children. In the 2018 outbreak in the Democratic Republic of the Congo, on 
the basis of the perceived risk–benefit ratio and some preliminary data, children as young as 
1 year of age were vaccinated.
Collection of data from pregnant women from past and ongoing studies is also important; 
very few safety data are available at present, as pregnancy is almost always an exclusion 
criterion in clinical trials. During the 2018 Ebola virus disease outbreak in the Democratic 
Republic of the Congo, pregnant women continued to be excluded from vaccination 
strategies.
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Furthermore, few data have been generated among high-risk immune-compromised 
populations, especially individuals infected by HIV. In the PREVAIL I trial, 5% of 
participants were HIV-infected, and, compared with non-HIV-infected individuals, their 
antibody response was lower at 1 month post vaccination: 48% for the chAd3-EBO-Z 
vaccine group and 62% for rVSVZEBOV vaccine group (vs 72% and 85% in non-HIV-
infected individuals).5 Additional data on safety and immunogenicity are needed in specific 
populations, including elderly people.
The durability and rapidity of immune responses also remain important areas of 
investigation. Whether the different vaccine approaches, including a prime-boost vaccination 
strategy, are able to confer longer-term protection remains to be shown. This information is 
especially important when considering a preventive vaccination strategy for at-risk 
populations, and specifically for health-care and front-line workers. Ongoing studies are 
assessing the durability of immunity, but only a small amount of data is available for up to 
24 months after vaccination. Additionally, rapidity of an effective immune response is likely 
to be an important determinant of the relative effectiveness of a vaccine in the context of ring 
vaccination. In the Ebola Ça Suffittrial, all clusters showed that, at 10 days or more after 
randomisation, there were no cases of Ebola virus disease among immediately vaccinated 
contacts and contacts of contacts; however, the majority of cases occurred before 10 days 
after randomisation in the immediate vaccination group.2
The correlation between immune response and clinical protection also remains a crucial, 
unanswered question. For Ebola virus disease, there is, as yet, no known correlate of 
protection. However, it remains important to do clinical trials investigating the durability of 
Ebola-specific immune responses. Ongoing efforts to assess possible correlates of protection 
include studies of vaccine efficacy and immunogenicity in non-human primates, and studies 
aiming to elucidate the interactions between Ebola virus disease and the immune system in 
humans (eg, in Ebola survivors). Should a correlate of protection be shown on the basis of 
these efforts, the immunogenicity data generated in vaccine studies in humans will be 
assessed according to that understanding.
Efficacy data from the Ebola Ça Suffit clinical trial show that no cases of the disease were 
reported more than 10 days after vaccination with rVSV-ZEBOV, whereas most phase 1 and 
2 studies have shown that titres of anti-Ebola virus glycoprotein IgG antibodies are not 
appreciably increased when measured 7 days after vaccination.5 These findings suggest that 
whatever early protection vaccines provide against Ebola virus might depend on immune 
mechanisms that are not measured by serum IgG antibody titres in currently available 
assays. Development of antigen-specific T cells and their cytokine profiles, as well as the 
induction of innate immune responses, will need to be directly analysed to understand earlier 
immune responses.26,27 Additionally, the correlates of immunity that reflect long-term 
clinical protection, and whether they are similar or different from those mediating immediate 
protection, need to be understood.28 Data from non-human primate models and clinical 
phase 1 studies of combined Ad26.ZEBOV and MVA-BN-Filo vaccination15 provide 
evidence of an important role for cellular immunity, particularly CD8-positive T cells 
producing tumour necrosis factor α and interferon γ (with or without interleukin 2). To 
date, no data have been published on cellular immune responses to the rVSV-ZEBOV 
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vaccine. T-cell responses to Ebola virus glycoprotein could be detected in 80% of volunteers 
after the prime Ad26.ZEBOV vaccination, were increased after the boost, and were 
sustained for at least 12 months after the prime in about 90% of volunteers vaccinated with 
Ad26.ZEBOV and MVA-BNFilo with a 56-day interval.15
Another unknown regarding vaccination relates to adverse events. Although few (if any) 
serious vaccine-related adverse events have been observed, and vaccines are at different 
stages of development, only additional large-scale trials will enable the overall safety of 
these products to be fully elucidated. This information is especially important given that the 
pathway to licensure for an Ebola virus vaccine, in the absence of definitive efficacy data in 
human clinical trials, might involve alternative regulatory pathways and could require 
postlicensure assessment of safety and clinical benefit. It is also important to better 
understand the mechanisms that lead to some of the observed adverse events, especially 
when these events have not been observed in all clinical trials homogeneously. In a Swiss 
cohort study7 investigating the effect of dose on the safety and immunogenicity of the rVSV-
ZEBOV candidate vaccine, dose reduction from 107 or more plaque-forming units (pfu) to 3 
× 10⁵ pfu decreased the occurrence and magnitude of recombinant vesicular stomatitis virus 
viraemia and reactogenicity, but did not prevent vaccine-induced oligoarthritis in ten (19%) 
of 53 vaccinees.7 The incidence of arthritis in the other phase 1, 2, and 3 trials of rVSV-
ZEBOV has been lower (<5%) across a large dose range, including doses of 1 × 10⁸ pfu or 
higher.2,7,8,10,11,29 A multivariate analysis indicated female sex (OR 2·2, 95% CI 1·1–4·1) 
and a medical history of arthritis (2·8, 1·3–6·2) as risk factors for the development of arthritis 
post vaccination. This analysis was done on results from a study conducted in the USA, 
Spain, and Canada with 1197 participants,7 and the analysis is now mentioned in the 
investigator’s brochure of the rVSV-ZEBOV vaccine.
The final unknown relates to community engagement and ongoing trust-building throughout 
the clinical trial process, which are crucial for participant retention and overall community 
support for the trial.30 Distrust towards a vaccination trial might exist in the population and 
negatively affect cooperation with the trial or even lead to suspension, as occurred in Ghana, 
where two Ebola vaccine trials were suspended because of negative rumours.31 Embedding 
social science research in the context of clinical trials can provide valuable insights that can 
mitigate distrust and support cooperation.
To build on the vaccine research studies that have been done thus far, the outstanding 
questions on the rapidity and durability of the immune response in adults, safety and 
immunogenicity in children, and the nature of the responses in immunocompromised and 
pregnant individuals using different vaccine strategies must be addressed. Improved 
understanding of humoral and cellular immune responses to Ebola vaccines is needed to 
identify correlates of protection. Answering these questions will require improvement of 
global capacity to continue research on Ebola vaccines, and collaborative partnerships are 
needed to optimise the chances of success. Several Ebola vaccine clinical trials in Africa, 
North America, and Europe have been done using such partnerships, including the EBOVAC 
projects, the Ebola Ça Suffit vaccination trial consortium, STRIVE, and PREVAIL.
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Against this backdrop, the Partnership for Research on Ebola Vaccinations (PREVAC) was 
established as an international consortium, including research and academic institutions (the 
French Institute for Health and Medical Research [Inserm], London School of Hygiene & 
Tropical Medicine, the US National Institutes of Health, and the Universities of Bordeaux 
and Minnesota), health authorities and scientists from four Ebola-affected countries (Guinea, 
Liberia, Sierra Leone, and Mali), nongovernmental organisations (the Alliance for 
International Medical Action and Leidos) and pharmaceutical companies (MSD, Johnson & 
Johnson, and Bavarian Nordic). This partnership was built to focus on Ebola research 
activities to prevent or respond effectively to the next potential Ebola outbreak. This 
consortium is currently conducting a randomised, double-blind, placebo-controlled trial of 
three Ebola vaccine strategies in adults and children (aged ≥1 year): (1) rVSV-ZEBOV 
prime without boost; (2) rVSV-ZEBOV prime followed by a rVSV-ZEBOV boost; and (3) 
Ad26.ZEBOV prime followed by MVA-BN-Filo boost. As of June, 2018, more than 2350 
adults and children have been recruited, and an additional 2500 enrolments are planned to 
achieve the target enrolment.
In summary, it is important to investigate different scenarios for vaccination strategies and 
different vaccines to respond more effectively to future outbreaks. These strategies include 
contact and post-exposure vaccination, targeted preventive vaccination, and widespread 
preventive vaccination of at-risk populations such as health-care workers and those residing 
in areas of re current outbreaks.
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